943141-58-0Relevant academic research and scientific papers
Novel non-ATP competitive small molecules targeting the CK2 α/β interface
Brear, Paul,North, Andrew,Iegre, Jessica,Hadje Georgiou, Kathy,Lubin, Alexandra,Carro, Laura,Green, William,Sore, Hannah F.,Hyv?nen, Marko,Spring, David R.
supporting information, p. 3016 - 3020 (2018/05/26)
Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2α and CK2β at the α-β interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 μM and a molecular weight of only 257 gmol?1 has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2α. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066
De Fusco, Claudia,Brear, Paul,Iegre, Jessica,Georgiou, Kathy Hadje,Sore, Hannah F.,Hyv?nen, Marko,Spring, David R.
supporting information, p. 3471 - 3482 (2017/05/29)
Recently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discov
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and
Dawson, Marcia I.,Xia, Zebin,Liu, Gang,Fontana, Joseph A.,Farhana, Lulu,Patel, Bhamik B.,Arumugarajah, Sankari,Bhuiyan, Mohammad,Zhang, Xiao-Kun,Han, Young-Hoon,Stallcup, William B.,Fukushi, Jun-Ichi,Mustelin, Tomas,Tautz, Lutz,Su, Ying,Harris, Danni L.,Waleh, Nahid,Hobbs, Peter D.,Jong, Ling,Chao, Wan-Ru,Schiff, Leonard J.,Sani, Brahma P.
, p. 2622 - 2639 (2008/02/04)
Apoptotic and antiproliferative activities of small heterodimer partner (SHP) nuclear receptor ligand (E)-4-[3′-(1-adamantyl)-4′- hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), which was derived from 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2-naphthalenec
